Company Profile: Kayothera, Inc.

Background

Kayothera, Inc. is a preclinical-stage therapeutics company specializing in the development of first-in-class, oral, small-molecule inhibitors targeting the retinoid nuclear receptor pathway. This pathway is implicated in various serious diseases, including cardiometabolic disorders and cancer. Founded in 2019 as a spinout from Princeton University, Kayothera is dedicated to pioneering therapies that address significant unmet medical needs in these areas.

Key Strategic Focus

Kayothera's strategic focus centers on:

Therapeutic Areas: Developing treatments for late-stage and metastatic cancers, such as breast, lung, pancreatic, colorectal, brain, and kidney cancers, as well as cardiometabolic diseases like Type 2 diabetes.

Technological Approach: Utilizing novel, orally available small molecules to inhibit the retinoid and rexinoid nuclear receptors, pathways known to drive adverse cardiometabolic and cancer outcomes.

Market Targeting: Addressing large patient populations with significant unmet medical needs by offering innovative therapeutic options.

Financials and Funding

As of July 2023, Kayothera has secured a total of $14 million in financial support, comprising:

Series A Financing: An $8 million round closed in March 2022, led by Accelerator Life Science Partners (ALSP).

Expanded Series A and Grants: An additional $5.2 million raised in July 2023, including grants from the National Institutes of Health (NIH) and The Andy Hill Cancer Research Endowment (CARE) Fund, along with further equity funding.

These funds are allocated to advance Kayothera's development programs in diabetes and oncology.

Pipeline Development

Kayothera's pipeline includes:

KAYO-1609: A first-in-class, oral inhibitor of the retinoid pathway, nominated as a development candidate for genetically defined oncology indications. IND-enabling studies commenced in Q3 2023, with an IND application to the FDA anticipated by the end of 2024.

KAYO-1732: A candidate targeting Type 2 diabetes, aiming to control blood glucose and lipid levels to prevent multiorgan degeneration in cardiometabolic syndrome and diabetes.

Technological Platform and Innovation

Kayothera's innovation is distinguished by:

Proprietary Technologies: Development of novel, orally available small molecules that inhibit the retinoid and rexinoid nuclear receptors, pathways previously considered undruggable.

Scientific Methodologies: Leveraging discoveries from Princeton University, the company employs advanced preclinical models to validate the efficacy and safety of its compounds.

Leadership Team

Mark Esposito, Ph.D.: Co-Founder and Vice President of R&D. Dr. Esposito's postdoctoral research at Princeton University laid the foundation for Kayothera's therapeutic approach.

Thong Q. Le: President and CEO. Mr. Le brings extensive experience in life sciences investment and company building, contributing to Kayothera's strategic direction.

Bruce L.A. Carter, Ph.D.: Chairman of the Board. Dr. Carter's background includes leadership roles at ZymoGenetics Inc. and Novo Nordisk A/S, providing valuable insights into drug development.

Paul Sekhri: Board Member. With over 30 years in the life sciences industry, Mr. Sekhri's experience spans senior management positions in pharmaceutical and biotechnology companies.

Leadership Changes

In October 2024, Kayothera announced the appointment of Dr. Bruce L.A. Carter as Chairman of the Board and Mr. Paul Sekhri as a Board Member, enhancing the company's leadership with substantial drug development and operational expertise.

Competitor Profile

Market Insights and Dynamics

The global oncology and cardiometabolic disease markets are substantial, with increasing demand for innovative therapies. The retinoid nuclear receptor pathway represents a novel target, offering opportunities for differentiation in these competitive fields.

Competitor Analysis

While specific competitors targeting the retinoid pathway are limited due to its previously undruggable nature, companies developing therapies for similar indications include:

Oncology: Firms focusing on immunotherapies and targeted treatments for metastatic cancers.

Cardiometabolic Diseases: Companies developing novel agents for Type 2 diabetes and related metabolic disorders.

Kayothera's unique approach to inhibiting the retinoid pathway positions it distinctively within these markets.

Strategic Collaborations and Partnerships

Kayothera has established significant partnerships to bolster its development programs:

Accelerator Life Science Partners (ALSP): Led both the initial and expanded Series A financings, providing strategic support and resources.

BioAdvance, Pier 70 Ventures, and WRF Capital: Participated in the expanded Series A financing, contributing to the company's financial strength.

National Institutes of Health (NIH) and The Andy Hill Cancer Research Endowment (CARE) Fund: Provided grant funding to support research and development efforts.

Operational Insights

Kayothera's strategic focus on the retinoid nuclear receptor pathway offers a competitive advantage by addressing previously undruggable targets. The company's emphasis on oral, small-molecule inhibitors enhances patient compliance and accessibility.